据最新发布的2024年报显示，K药Keytruda（帕博利珠单抗）在2024年以294.82亿美元营收成功卫冕全球“药王”，司美格鲁肽2024年营收292.96亿美元，两者相距不到2亿美元。

Com a patente do medicamento prestes a expirar, o setor de saúde brasileiro pode passar por grandes mudanças, com impacto em ...

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are ...